Axis Securities projects a 7% revenue increase for the pharma sector in Q2FY27, though profitability remains challenged. While domestic growth in chronic therapies stays steady at 10-12%, margin headwinds persist due to US-centric pricing issues and R&D costs. Conversely, the hospital segment remains resilient with projected 17.5% revenue growth, driven by specialty demand. Aarti Drugs, Gland Pharma, and KIMS emerge as the brokerage's top earnings picks for the quarter.
Axis Securities Q2FY27 Pharma and Hospital Sector Forecast
Revenue: Rs 40,903 Cr (Pharma Sector) | EBITDA: Rs 8,308 Cr (Pharma Sector)
Reader Takeaway: Domestic demand and hospital expansion drive growth, but US pricing pressures and new facility costs weigh on margins.
What just happened
Axis Securities has released its quarterly outlook for the Indian pharmaceutical and hospital sectors for Q2FY27. The report highlights a divergence between the two segments: pharmaceutical companies are expected to see moderate revenue growth alongside margin contraction, while hospitals continue to show strong top-line momentum driven by specialty services.
Why this matters
For investors, the report quantifies the impact of US market challenges—such as price erosion and the earnings drag from legacy generic products—on Indian pharma profitability. Meanwhile, the hospital sector's performance is being shaped by the balance between aggressive capacity expansion and the operational costs associated with ramping up new units.
Key Trends
- Pharma: Revenue is projected to rise 7% YoY to Rs 40,903 Cr, but adjusted PAT is expected to decline by 19.6% due to high R&D spending and pipeline commercialization costs.
- Hospitals: The sector is expected to deliver 17.5% YoY revenue growth. Specialty segments like oncology and cardiology remain the primary contributors to this performance.
- Margin Outlook: Pharma margins are under pressure from declining high-margin generics. Hospital margins are estimated at ~23.1%, up from 22.0% in Q1FY27, despite the initial drag from new asset investments.
Risks to watch
- US Business: Price erosion and limited new launches remain significant hurdles for major players.
- Regulatory Environment: Potential price caps on essential medicines and hospital bed tariffs represent persistent downside risks for earnings visibility.
- Operational Costs: The high ramp-up costs of new hospital beds can temporarily suppress EBITDA growth for healthcare providers until utilization rates normalize.
What to track next
Investors should monitor management commentary regarding new US product approval timelines and the profitability trajectory of newly commissioned hospital units in regions like Nashik and Kerala.